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Dichloroacetate (DCA) is a xenobiotic of interest to both environmental toxicologists and
clinicians. The chemical is a product of water chlorination and of the metabolism of various drugs
and industrial chemicals. Its accumulation in groundwater and at certain Superfund sites is
considered a potential health hazard. However, concern about DCA toxicity is predicated mainly
on data obtained in inbred rodent strains administered DCA at doses thousands of times higher
than those to which humans are usually exposed. In these animals, chronic administration of
DCA induces hepatotoxicity and neoplasia. Ironically, the DCA doses used in animal toxicology
experiments are very similar to those used clinically for the chronic or acute treatment of several
acquired or hereditary metabolic or cardiovascular diseases. As a medicinal, DCA is generally well
tolerated and stimulates the activity of the mitochondrial pyruvate dehydrogenase enzyme
complex, resulting in increased oxidation of glucose and lactate and an amelioration of lactic
acidosis. By this mechanism, the drug may also enhance cellular energy metabolism. DCA is
dehalogenated in vivo to monochloroacetate and glyoxylate, from which it can be further
catabolized to glycolate, glycine, oxalate, and carbon dioxide. It remains to be determined
whether important differences in its metabolism and toxicology exist in humans between
environmentally and clinically relevant doses. - Environ Health Perspect 106(Suppl 4):989-994
(1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-4/989-994stacpoole/abstract.html
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Introduction
Dichloroacetate (DCA) is one ofa host of
organohalides to which humans have long
been chronically exposed. Environmental
sources ofDCA include chlorinated drink-
ing water (1-3) and groundwater contami-
nation by certain industrial solvents and
other chlorinated precursors (4). DCA is
also a metabolite in the biotransformation
ofseveral pharmaceuticals (5,6) and has
been administered orally and parenterally
for decades as an investigational drug for
the treatment of numerous cardiovascular
and metabolic disorders. Collectively, these
data indicate that daily human exposure to
DCA encompasses a 10,000-fold concen-
tration range, from approximately 4 pg/kg
consumed in finished drinking water to
approximately 50 mg/kg administered for
therapeutic purposes.
A comparative assessment ofthe kinet-
ics, metabolism, and toxicology ofDCA in
animals and humans has recently been
summarized (7). Here we focus on the clin-
ical pharmacology and safety ofthis unusual
chemical, based in large part on inves-
tigations conducted in healthy volunteers
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From a medicinal standpoint, a principal
site ofaction ofDCA is the pyruvate dehy-
drogenase (PDH) enzyme complex (PDC)
located in the mitochondrial inner mem-
brane. PDC catalyzes the reversible decar-
boxylation ofpyruvate to acetyl coenzyme
A (CoA), which is the rate-limiting step in
the aerobic oxidation ofglucose, pyruvate,
and lactate in animal cells (Figure 1).
PDC undergoes rapid posttranslational
modulation in activity, due in part to
reversible phosphorylation. PDC kinase
phosphorylates and inactivates PDC,
whereas PDC phosphatase dephosphorylates
the complex and restores catalytic activity.
DCA inhibits the kinase, thereby locking
PDC in its unphosphorylated active form.
This effect occurs within minutes oforal or
parenteral administration ofDCA, which is
rapidly transported across cell membranes
via the monocarboxylate carrier (8) and is
concentrated in mitochondria (5).
The ability ofmitochondria to oxidize
substrates and produce adenosine triphos-
phate (ATP) by oxidative phosphorylation is
integral to normal homeostasis and to the
ability of cells to survive in the face of
impending energy failure. Experimental and
clinical investigations with DCA suggest
that the drug primes the tricarboxylic acid
(TCA) cycle with acetyl groups and the res-
piratory chain with electrons donated by the
reducing equivalents generated by the PDC-
and TCA-cycle-catalyzed reactions, thereby
promoting ATP synthesis (Figure 2) (5).
The ability of DCA to stimulate the effi-
cient conversion ofsubstrate fuel (glucose or
lactate) into energy provides a biochemical
rationale for its utility in ameliorating
acquired or congenital causes oflactic acido-
sis and other pathologic conditions associ-
ated with mitochondrial energy failure.
Indeed, studies by many investigators have
firmly established DCA as the most potent
lactate-lowering agent ever used clinically
and a potential treatment for myocardial
ischemia or failure (9).
Kinetics and Metabolism
Dichloroacetate is rapidly and virtually
completely absorbed following oral dosing
and about 20% is bound to human plasma
proteins (10). In all species examined to
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Figure 1. Site ofaction of dichloroacetate. DCA inhibits the mitochondrial enzyme PDH kinase, th(
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Figure 2. Cellular metabolism of glucose and oxidative phosphorylation. By activating the PD(
TCA cycle with acetyl-CoA molecules derived from glucose. Reducing equivalents, in the form al
adenine dinucleotide and reduced flavin adenine dinucleotide from the PDC and TCA, reactions
(e- Ito the respiratory chain, leading to the reduction of oxygen to water and to the synthesis of
sine diphosphate. Reproduced from Stacpoole et al. (13) with permission of the BMJ Publishing C
date, the first dose is cleared from plasma
more rapidly than subsequent doses,
although the mechanism for this effect is
unknown. Also unclear is the quantitative
importance ofitsvaried metabolic routes and
the influence of repeat administration
thereon. Glyoxylate is an intermediate in
DCA metabolism, and oxalate and CO2 are
terminal end products. Neither glyoxylate
nor oxalate stimulate PDC activity (5).
However, because the actions of DCA in
humans often persist several days after its
clearance from plasma (5), it is possible
PDH-P, inactive that other reactive intermediates of DCA
accumulate intracellularly at active sites and
bind covalently to target proteins, or that
DCA (or a metabolite) induces enzymes
responsible for its pharmacodynamic effects.
DCA is extensively metabolized in
rodents and humans, with little ofthe dose
excreted unchanged (7). Although most
drug metabolism studies have been
erebymaintaining prompted by concern about DCA as a
ation ofglucose. potential environmental pollutant, nearly
all experiments to date have administered
doses to animals and humans in the thera-
peutic (i.e., milligram per kilogram) rather
than the environmental (microgram per
kilogram) range. Thus, it remains unknown
whether the kinetics and metabolism ofthe
compound differ at these extremes of
human exposure.
Adults
To investigate the in vivo metabolism of
DCA in humans, we recently developed
and validated a gas chromatography/mass
spectrometry technique that simultaneously
measures DCA and its metabolites mono-
chloroacetate (MCA), glyoxylate, glycolate,
and oxalate in human plasma (11). Follow-
ing administration of [13C1,2] DCA, the
drug and its metabolites are derivatized to
their methyl esters by reacting them with a
ATP 12% BF3-methanol mixture. Lactate, a gly-
colytic end product that is frequently mea-
H20 sured following DCA administration, can
also be quantitated bythis technique.
Healthy men and women 18 to 65
iratory years of age receive sequential oral DCA
1a0 doses of 25 mg/kg and 250, 25, and 2.5
jpg/kg daily for 5 consecutive days. The
highest and lowest doses are also adminis- n102 tered intravenously for 5 days. The order
oforal versus intravenous administration
for these doses is randomized. This spec-
DCA primes the rum of DCA doses allows us to compare
reducednicotine the kinetics and metabolism in each gender
donate electrons during exposure to both environmentally
f ATP from adeno- and clinically relevant levels, i.e., over a
iroup. 10,000-fold concentration range. A 2- to
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3-month washout period occurs between
studies, as our previous investigations
(10,12) demonstrated that an initial DCA
dose in healthy subjects increases the
plasma t112 ofa subsequent dose, even after
awashout period ofseveral weeks.
These ongoing studies were initiated
using the 25 mg/kg dose for two practical
reasons: first, to optimize our chances of
identifying metabolites of ['3C]DCA in
plasma and urine, and second, to generate
comparative data with our pediatric investi-
gations early on. Table 1 summarizes the
mean data analyzed to date from 18 subjects
who received oral or intravenous DCA for 5
days. On days 1 and 5, detailed kinetic
investigations were performed over 24-hr
sample collection periods. Subjects received
a 1:1 mixture of [13C] and [12C]DCA on
these days and [12C]DCAon days 2 to 4.
In general, the kinetic profile of a
25-mg/kg dose appears to be independent
ofgender and administration. Peak plasma
concentration (Cmax) did not change
appreciably between genders or between
the first and fifth intravenous doses, but
the Cm,, after the final oral dose (158±99
pg/ml) was 68% greater than after the ini-
tial dose (94 ±45 pg/l). We speculate this
difference may reflect faster gastrointestinal
absorption of DCA upon repeated admin-
istration, perhaps by induction of some
transport mechanism. Chronic dosing in
all subject categories led to a striking
increase in tl12, and this was associated
with a fall in plasma clearance and an
increase in the area under the plasma con-
centration curve (AUC). Urinary DCA
accounts for approximately 1 to 2% ofthe
administered initial dose and approxi-
mately 3 to 5% ofthe fifth dose, based on
24-hr urine collections.
Figure 3 shows representative plasma
concentrations of [13C]DCA (Figure 3A)
and its metabolites (Figure 3B) after a 25-
mg/kg dose infused over 10 min. Note the
rapid rise and fall ofMCA, which in some
subjects may reach levels up to 10% ofthe
DCA Cmax on a molar basis. Glyoxylate
and oxalate concentrations, although
measurable, are usually lower than MCA
during the first 4 hr after dosing.
Children
The term congenital lactic acidosis (CLA)
refers to a group of rare inborn errors of
metabolism variably characterized by
progressive neuromuscular deterioration
and accumulation of lactate and hydrogen
ions in blood, urine, or cerebrospinal fluid,
frequently resulting in early death. The
incidence and prevalence in the United
States are approximately 250 and 1000
cases, respectively. Most identifiable causes
involve inherited or spontaneous mutations
in PDC or in one or more enzymes ofthe
respiratory chain. More than 50 CLA
infants and children worldwide have
received oral or intravenous DCA (13) in
open-label investigations. Drug dose and
treatment duration varied widely. Twelve
patients received DCA for at least 1 year
and three received it for at least 5 years.
Thus, the cumulative DCA treatment
experience in CLA infants and children is
greater than 41 patient-years.
A controlled clinical trial is now being
conducted to test the central hypotheses
that DCA is safe and improves the quality
Table 1. Dichloroacetate kinetics in healthy adults.
Cmax, pg/mI AUC, hr pg/min Clearance, mI/min/kg Half-life, hr
Category n Day 1 Day 5 Day 1 Day 5 Day 1 Day5 Day 1 Day5
Entire group 28 129±73 163±84 229±138 1334±763 0.160±0.10 0.025±0.01 1.07±0.43 9.10±8.46
Female 14 132±76 146±64 255±144 1351 ±833 0.130±0.06 0.024±0.01 1.15±0.40 9.49±7.15
Male 14 126±70 180±98 203±127 1298±684 0.190±13 0.026±0.02 0.98±0.45 8.71 ±9.57
Treatment 1 18 136±82 154±71 237±145 1318±871 0.160±0.11 0.026±0.01 1.03±0.40 8.56±7.10
Treatment2 10 117±53 181 ±102 216±125 1336±515 0.162±0.09 0.024±0.01 1.12±0.49 10.05±10.39
Intravenous 14 165±79 168±66 263±151 1374±876 0.150±0.12 0.026±0.02 1.19±0.48 7.73±4.94
Oral 14 94±45 158±99 196±114 1275±626 0.170±0.08 0.025±0.01 0.94±0.34 10.47±10.72
n, number of kinetic studies. "Data are means ±SD.
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Figure 3. Plasma concentrations of (A) [13C]dichloroacetate and (B) its metabolites after a 25-mg/kg infusion of [13C]DCA. Note the rapid appearance and disappearance in
plasma of MCAfollowing the administration of DCA.
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oflife and metabolic status ofinfants and
children with CLA due to PDC or respira-
tory chain defects. Safety is determined
principally by finding that chronic DCA
does not cause hepatocellular, peripheral
nerve, ocular, or renal toxicity (all ofwhich
have been reported in dosed animals) or
toxicity related to other organ systems.
Quality oflife is quantified bysuch key bio-
logic indices ofdrug efficacy as improve-
ment in neurologic, neurobehavioral, and
physical function and by reduction in the
frequency and severity ofhospitalizations
due to acid-base decompensation or other
CLA-related complications. Biologic
markers of cellular energy metabolism
that are measured include blood and cere-
brospinal fluid lactate (which should fall
because of DCA's mechanism of action)
and height (which should increase because
of the amelioration of the metabolic aci-
dosis). Improvement in these markers
should track closely with quality of life
indices. In addition, the kinetics and
metabolism of [13C] and ['2C]DCA are
examined prospectively and are interpreted
Table 2. Plasma dichloroacetate kinetics in a child
with congenital lactic acidosis.
Treatment
time
Day 1, first dose
Day 5
Month 3
Month 9
Half-life,
hr
0.74
2.35
6.06
7.47
Cmax'
pg/mI
39
51
115
154
Cmin,
pg/mI
0
0
46
38
Cmij, minimum plasma concentration.
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in light of the dynamic and toxicologic
effects ofthe compound.
['3C]DCA kinetics are performed at
entry with a 2.5-pg/g dose of compound
and 3 to 4 times with 12.5 mg/kg DCA
during the initial 24-month period. The
dose of2.5 pg/kg is chosen because it is too
small to exert any important pharmacody-
namic effect and because it reflects the
amount expected to be consumed by envi-
ronmental exposure. Thus, the study affords
the opportunity to examine repeatedly the
kinetics and metabolism of DCA during
both environmental and dinical dosephases.
Table 2 and Figure 4 showrepresentative
data on DCA kinetics and metabolism in
CLA patients. The patient in Table 2
received 12.5 mg/kg every 12 hr by mouth.
Cmax levels were usually achieved 1 hr after
the dose and minimum plasma levels were
obtained at the dosing interval. In a second
patient, Figure 4 illustrates the expected
change in plasma drug clearance. In sharp
contrast to our prior studies in adults with
acquired causes oflactic acidosis (14,15) or
in healthy volunteers, both Table 2 and
Figure 4 demonstrate that repeated dosing
in children appears to lead to progressive
increases in Cmax. Figure 5 illustrates the
plasma metabolism ofan oral 12.5 mg/kg
dose ofDCA (1:1 isotope ratio) in a child
with CLA. As with healthy adults, MCA is
an immediate and short-lived product,
whereas glyoxylate and oxalate have more
protracted time courses.
In the CLA study, children are admin-
istered 50 mg/kg chloral hydrate (CH) by
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Figure 4. Change in dichloroacetate kinetics after 6 months in a patient with con-
genital lactic acidosis. Note the increase in the peak plasma concentration and the
decrease in plasma clearance in DCAfollowing chronic oral administration.
mouth to induce short-term conscious
sedation for various neurologic tests.
During the course of our DCA kinetic
experiments, we noted the presence of a
major interfering substance in some plasma
samples. We determined this substance was
CH and, in the course ofthese investiga-
tions, discovered that DCA is a major
metabolite ofCH in humans (6). We also
found that CH and DCA may compete for
similar routes ofbiotransformation. This
conclusion is based in part on the observa-
tion that prior administration of CH
delays the plasma clearance ofDCA.
The discovery that humans catabolize
CH to DCA has important implications
for the kinetics, dynamics, and toxicology
of both compounds. Both are found in
microgram per liter quantities in municipal
drinking water and are considered by the
U.S. Environmental Protection Agency to
be environmental hazards. The interesting
possibilities are raised that the mental sta-
tus changes induced by CH and (in some
individuals) DCA may have a common
mechanism and that CH may alter inter-
mediary metabolism in the host by virtue
ofits conversion to DCA.
Toxicology
A valid assessment of the human risk of
DCA is confounded by the fact that most
animal toxicology has focused on its
chronic administration to subprimates, usu-
ally at doses nearer to those used clinically
than to levels anticipated from environmen-
tal exposure ofthe chemical, its precursors,
- & - Oxalate
-.--*- Glyoxylate
-0-- MCA
p 9
8 12 16 20 24
Time, hr
Figure 5. DCA metabolites for [13C]dichloroacetate in a patient with congenital lac-
tic acidosis: first DCA treatment. The plasma concentration of MCA peaks and
decays rapidlyfollowing a single dose of DCA.
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or its catabolites. The animal toxicology of
DCA has recently been reviewed (7). In
brief, the liver, kidney, nervous system,
testes, and eye are potential target organs of
chronic DCA toxicity. Studies in rats and
mice have shown that DCA can induce
hepatocellular injury, hypertrophy, hyper-
plasia, adenomas, and carcinomas after
chronic oral exposure to levels similar to
those administered clinically (7).
To date, evidence ofDCA toxicity in
humans is limited and is primarily restricted
to the nervous system and the liver.
Approximately 50% of healthy adults
receiving single or repeated oral or intra-
venous doses of 25 or 50 mg/kg DCA
exhibit anxiolytic or sedative effects. These
symptoms usually occur within 60 min of
drug administration and may last several
hours (16,17). Mild drowsiness or dimin-
ished anxiety have also been observed in a
few patients with diabetes mellitus (18) or
lactic acidosis (14) treated briefly with
DCA. These central nervous system changes
occur unpredictably and without obvious
predilection for any particular gender, race,
agegroup, or route ofdrugadministration.
A reversible peripheral neuropathy
occurred after several months ofdaily oral
50 to 100 mg/kg DCA treatment in two
children with CIA due to PDC deficiency
or a respiratory chain defect (7). Return to
pretreatment neurologic states was
achieved, both clinically and by nerve con-
duction velocity testing, within 6 months
ofdiscontinuing DCA. In the patient with
PDC deficiency, resolution ofthe neuropa-
thy led to retreatment with DCA at doses
of 10 to 25 mg/kg/day, which has been
continued for over 2 years without evidence
ofperipheral neuropathy.
Mild (-2-fold) asymptomatic elevation
ofserum transaminases has been noted in at
least two children with CIA (17) and may
reflect hepatocellular damage. Both patients
received 25 to 75 mg/kg DCAdaily for sev-
eral months. Reduction in the highest dose
Glycolate oxidase
HO- CH2-COO- Glycolate dehydrogenase Glycolate
cl Lactate dehydrogenase
Dehalogenation Lactate oxidase e H-C-COO-
- ? - 0= CH COO- L oxdaeC C |=
CH -COO- Glycolate oxidase
Glyoxylate Oxalate
Dichloroacetate Oxidation
Glycolate aminotransferase Reduction to CO2
H2N -CH2- COOH
Cl- CH2 COO- Glycine
Monochloroacetate
Figure 6. Biotransformation of dichloroacetate. This scheme postulates the existence of two principal in vivo
routes of dichloroacetate catabolism: by reduction to MCA and by oxidation to glyoxylate. The sites and mecha-
nism(s) for dehalogenation are uncertain. Glyoxylate and its catabolites are all naturally occurring endogenous
molecules. Formation ofglycine provides a route of entry of DCA into the general carbon pool ofthe host.
to the lowest dose in one subject led to
normalization oftransaminase levels. There
is no clinical evidence that DCA is toxic to
the eyes, kidneys, or gonads or induces
neoplasia in anyhuman tissue.
Summary and Conclusions
Together, the results of these and other
(5,7) investigations indicate that the kinet-
ics and biotransformation of DCA are
qualitatively similar when the chemical is
administered to children or adults at thera-
peutically relevant doses, as depicted in
Figure 6. DCA, and/or an intermediate,
strongly inhibits its own metabolism, but
the mechanism for this is unknown.
Likewise, the quantitative significance of
the putative pathways ofits metabolism in
any species remains to be determined, as
do the early molecular events in the
dehalogenation of DCA. The chemical
appears to be relatively nontoxic when
administered acutely and parenterally to
healthy adults or to critically ill patients
with acquired causes oflactic acidosis, but
its long-term safety can be more adequately
addressed by chronic treatment ofchildren
with CLA.
DCA is unique among chlorinated
hydrocarbons in that research on its kinet-
ics, metabolism, and toxicology has been
driven byboth environmental and therapeu-
tic concerns. The interesting consequence is
that much ofthe animal experimentation
has been conducted using doses much closer
to those used clinically than to levels to
which human populations may be exposed,
either bychlorination ofmunicipal drinking
water or by groundwater contamination as
occurs, for example, at certain Superfund
sites. Thus, very little animal and almost no
human studies have examined the pharma-
cology or toxicology ofDCA at environ-
mentally relevant concentrations. Therefore,
the appropriateness ofextrapolating animal
toxicology studies to humans in determin-
ing the health risk from DCA exposure is
problematic thus far. In fact, this caveat may
apply to the extrapolation of nonhuman
toxicologic data generated for a number of
chlorinated hydrocarbons, induding precur-
sors ofDCA. In the case ofDCA, however,
its status as an investigational drug for both
pediatric and adult diseases affords an
invaluable opportunity to prospectively
assess its chronictoxicity in humans.
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